Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Eli Lilly is a global pharmaceutical manufacturer with dominant positions in diabetes (Mounjaro, Trulicity), obesity (Zepbound), and oncology (Verzenio). The company's GLP-1 franchise (tirzepatide) is driving exceptional growth with 44.7% revenue expansion, capturing significant market share in the $100B+ cardiometabolic market. With 83.8% gross margins and 114.6% ROE, Lilly operates a high-margin, patent-protected business model with substantial pricing power.
Lilly generates revenue through patent-protected branded pharmaceuticals sold to wholesalers, pharmacy benefit managers, and hospitals globally. The company's 83.8% gross margin reflects minimal manufacturing costs relative to pricing power derived from clinical differentiation and patent exclusivity. Mounjaro/Zepbound command premium pricing ($1,000-$1,350/month) due to superior efficacy (21% weight loss vs 15% for competitors) and dual GIP/GLP-1 mechanism. Operating leverage is substantial as R&D and SG&A are largely fixed - incremental revenue from blockbuster launches flows directly to operating income (45.6% operating margin). The company is investing $7.8B in capex to expand GLP-1 manufacturing capacity, indicating supply constraints rather than demand issues.
Mounjaro/Zepbound prescription trends and market share vs Novo Nordisk's Ozempic/Wegovy - weekly TRx data from IQVIA/Symphony
Clinical trial readouts for tirzepatide in sleep apnea, heart failure, and MASH (non-alcoholic steatohepatitis) - label expansion drives addressable market
Manufacturing capacity announcements and supply availability - current constraint on revenue growth
Medicare/Medicaid coverage decisions for obesity drugs - potential $50B+ market expansion if Part D covers weight loss
Pipeline progress in Alzheimer's (donanemab), obesity (orforglipron oral GLP-1), and next-gen incretin therapies
Patent cliffs on legacy products (Trulicity loses exclusivity 2027, Humalog/Humulin face biosimilar competition) - requires pipeline execution to offset $8B+ revenue erosion
Drug pricing legislation and IRA negotiations - Medicare can negotiate prices on drugs 9+ years post-approval starting 2026, potentially impacting Trulicity and future blockbusters
Obesity drug safety concerns - long-term cardiovascular and gastrointestinal safety data still emerging, potential for black box warnings or usage restrictions
Novo Nordisk's semaglutide franchise (Ozempic/Wegovy) maintains 60%+ market share in GLP-1 category - Lilly must execute on superior efficacy messaging and supply availability
Oral GLP-1 competition from Novo's rybelsus and Lilly's own orforglipron could cannibalize injectable franchise at lower price points
Amgen, Pfizer, and Viking Therapeutics developing next-generation obesity drugs with potentially superior profiles - risk of leapfrogging current GLP-1 standard of care
1.79x debt/equity elevated for pharmaceutical sector - driven by $7.8B capex program and M&A activity, though $16.8B OCF provides 2.2x interest coverage
Pension and post-retirement benefit obligations typical of legacy pharmaceutical company - not material relative to $932B market cap
low - Pharmaceutical demand is non-discretionary and driven by disease prevalence rather than GDP. However, GLP-1 obesity drugs have some discretionary exposure as many patients pay out-of-pocket ($1,000+/month) without insurance coverage. Consumer confidence and discretionary income affect cash-pay obesity segment, but diabetes indication (80% of Mounjaro sales) is fully insulated.
Moderate sensitivity through valuation multiples rather than operations. With 1.79x debt/equity and $16.8B operating cash flow, financing costs are manageable. However, at 14.3x P/S and 34.5x EV/EBITDA, Lilly trades at growth stock multiples - rising 10-year Treasury yields compress these multiples as discount rates increase. The company's $7.8B capex program is internally funded, minimizing direct rate impact on operations.
minimal - Pharmaceutical sales are primarily to investment-grade wholesalers (McKesson, AmerisourceBergen, Cardinal Health) with 30-60 day payment terms. Government payers (Medicare/Medicaid ~40% of revenue) have zero credit risk. The 1.55x current ratio and $16.8B operating cash flow provide substantial liquidity cushion.
growth - Despite $932B market cap, 44.7% revenue growth and 94.9% earnings growth attract growth-at-reasonable-price investors. The GLP-1 franchise offers multi-year 20%+ growth runway with $50B+ peak sales potential. Institutional ownership is high given S&P 500 index weight, but momentum investors drive recent 57.5% six-month return.
moderate - Beta approximately 0.8-0.9 given large-cap pharmaceutical defensive characteristics, but clinical trial binary events (donanemab, orforglipron readouts) and competitive GLP-1 dynamics create episodic volatility. The 1.7% three-month return vs 57.5% six-month return shows momentum-driven swings.
